Search Results

Filter

Results (14)

Ohio Gov. Mike DeWine and Claire Blevins, RN, a childhood leukemia survivor.

Cancer and Blood Diseases

$1.48M State Grant Boosts ENGRAFT Learning Network

Ohio Gov. Mike DeWine stopped by Cincinnati Children’s on Dec. 5 to announce a major boost for pediatric cancer research—a $1.48 million grant to power the ENGRAFT learning network. This collaborative effort brings together experts, families, and partners to transform outcomes for kids needing stem cell transplants, as part of a $5 million statewide investment in fighting childhood cancer.

Cincinnati Children’s GXP Specialist Jeremy Crawford demonstrates work inside a cleanroom, Wednesday, Nov. 12, 2025, at the Applied Gene and Cell Therapy Center in Sharonville, Ohio.

Cancer and Blood Diseases

A Bold Investment to Make the Future of Medicine Happen

The new Applied Gene and Cell Therapy Center will expand capacity for manufacturing viral vectors and cell-based products under Current Good Manufacturing Practice conditions, supporting complex trials in oncology, hematology and rare genetic disorders, with capabilities for large-scale bioreactor production and post-approval therapy manufacturing.

Heart Institute (CICU) photoshoot. This shoot was done to highlight what goes on in the unit and also highlight the Doctors, RN's and RT's in the unit, the surgery team performing a procedure led by Krystal Nymberg and Dr. David Lehenbauer.

Cancer and Blood Diseases

Advanced Surgical Skills, Technology Yield Strong Outcomes

Cincinnati Children’s surgeons use advanced minimally invasive, fluorescence-guided, robotic and HIPEC techniques to improve outcomes for complex pediatric tumors.

Patient Saniya Hackworth is seen clinic by Dr. Russell Ware. Saniya has sickle cell anemia.

Cancer and Blood Diseases

Advancements Bring New Hope for Sickle Cell Disease

A Phase II clinical trial conducted in Ghana suggests that hydroxyurea — already a treatment offered for the most common form of sickle cell disease — also shows benefits for those with the hemoglobin SC (HbSC) variant of the condition.

CBDI photoshoot, Issac Choi, and Sophia Philbrook

Cancer and Blood Diseases

Advancing Lifesaving Therapies for Myeloid Malignancies

Discover how Cincinnati Children’s is accelerating research and clinical trials to advance therapies for myeloid malignancies across all age groups.

A learning health network meeting.

Cancer and Blood Diseases

Cincinnati Children’s Launches ENGRAFT Network

ENGRAFT, a new learning health network led by Cincinnati Children’s, brings together pediatric and adult centers to improve transplant and cellular therapy outcomes.

pictured, Thursday, July 10, 2025, Cincinnati Children’s Burnett.

Cancer and Blood Diseases

Expanding Expertise with 10 New Faculty in Pediatric Cancer and Blood Disorders

Meet the experts joining the Cancer and Blood Diseases Institute to advance care and research in pediatric oncology, hematology, bone marrow transplantation and proton therapy.

Cincinnati Children’s pediatric hematologist and oncologist Dr. Ashish Kumar examines patient Eli Storz, pictured, Friday, Jan. 24, 2025, at the Burnet Campus of Cincinnati Children’s.

Cancer and Blood Diseases

New Faculty Enhance Pediatric Cancer and Blood Disease Care

Specialists in oncology, hematology, bone marrow transplantation and proton therapy join the Cancer and Blood Diseases Institute to enhance precision medicine and multidisciplinary care.

Hematology(CBDI) Summer shoot, which took place at Washington park and Alms park. Patients from the department are seen in these photos., Ty' legend Thompson.

Cancer and Blood Diseases

Novel Tests for Pediatric Cancer Diagnosis and Monitoring

Cincinnati Children’s unveils advanced genomic tools for pediatric cancer care—CinCSeq and Histiotrak offer faster, more precise diagnostics and monitoring.

A photo of a CBDI patient.

Cancer and Blood Diseases

Off-the-Shelf CAR T-Cell Therapy Evaluates Survival in Relapsed T-ALL/LBL

A look at how Cincinnati Children’s is advancing care for relapsed T-ALL and T-LBL through a novel CAR T‑cell therapy, offering new hope for resistant disease.

10 of 14